ICCC
Immucell Corp /De/
$11.46
+0.83 (+7.81%)
At close · Jul 9
Market Cap
$99.92M
Shares
9,046,799
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.46
Open$10.52
Day$10.52–11.50
52W$4.52–11.50
Avg vol 30d28K
Short int12K · 0.1% float · 1.0d
Short vol40%
Last earningsJul 9, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+61%
above
Price vs 50-day avg
+20%
above
RSI (14)
69
neutral
MACD trend
Positive
52-week position
99%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+18%
trailing
6-month return
+73%
trailing
YTD return
+86%
this year
Relative strength
+66%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow
Distributing
1 of 27 funds reported for Jun 30 · net -9.0K sh shares
Insider flow
Accumulating
Net +$76.0K over 90 days · 0% sells
Short interest
Rising
0.14% of float · ▲ +35.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
27 holders — mid 3-yr range
Squeeze score
24
low risk · 0–100
Fundamentals
Revenue growth
+52%
Y/Y
Gross margin
43%
contracting
EPS growth
+54%
Y/Y
Free cash flow
$1.2M
Balance sheet
$5.3M
net debt
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Sep 28, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+61%
Bullish
Price vs 50-day avg
+20%
Bullish
RSI (14)
69
Neutral
MACD trend
Positive
Bullish
52-week position
99%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow
Distributing
1 of 27 funds reported for Jun 30 · net -9.0K sh shares
Insider flow
Accumulating
Net +$76.0K over 90 days · 0% sells
Short interest
Rising
0.14% of float · ▲ +35.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
27 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $5
Now $11 · 99%
52-wk high $12
vs 200-day avg +61%
vs 50-day avg +20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Domestic Sales | $6.2M | Three Months Ended June 30 | — |
| Dual-Force® and Other Sales | $4.8M | Six Months Ended June 30 | — |
| International Sales | $1.6M | Six Months Ended June 30 | — |
| Tri-Shield First Defense® Sales | $12.8M | Six Months Ended June 30 | — |
| Average manufacturing units per month | 450,000 | Q1 2026 | — |
| cash on hand | $6.8M | Q1 2026 call | — |
| EBITDA non-GAAP | $2.6M | Q1 2026 call | +13.0% |
|
|
|||
| gross margin percentage | 45% | Q1 2026 call | — |
| inventory | $8.7M | Q1 2026 call | — |
| share of animals treated | 18.1% | Q1 2026 call | — |
| share of U.S. category spend | 35.2% | Q1 2026 call | — |
| U.S. scours biologics category spend growth | 11% | Q1 2026 call | — |
| working capital | $15M | Q1 2026 call | — |
| average monthly output | 380,000 | the year ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ICCC
this stock
Immucell Corp /De/
|
$99.92M | +86.3% | +51.6% | — | 0.1% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ICCC | +4.2% | +18.3% | +73.1% | +14.0% | +86.3% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +4.4% | +17.4% | +65.7% | +14.2% | +77.0% |